Background
Methods
Human uterine cervix samples
Epithelial raft cultures
Immunohistochemistry
Protein | Antigen retrieval | Antibody | Antibody dilution and incubation time |
---|---|---|---|
MCT1
| Citrate buffer (0.01 M, pH = 6), 98°C, 20’ | AB3538P | 1:200, overnight |
Chemicon International | |||
MCT2
| Citrate buffer (0.01 M, pH = 6), 98°C, 20’ | sc-50322 | 1:200, 2 hours |
Santa Cruz Biotechnology | |||
MCT4
| Citrate buffer (0.01 M, pH = 6), 98°C, 20’ | sc-50329 | 1:500, 2 hours |
Santa Cruz Biotechnology | |||
CD147
| EDTA (1 mM, pH = 8), 98°C, 20’ | sc-71038 | 1:400, overnight |
Santa Cruz Biotechnology | |||
GLUT1
| Citrate buffer (0.01 M, pH = 6), 98°C, 20’ | ab15309-500 | 1:500, 2 hours |
AbCam | |||
CAIX
| Citrate buffer (0.01 M, pH = 6), 98°C, 20’ | ab15086 | 1:2000, 2 hours |
AbCam | |||
VEGF-A
| CC1 (pH = 8,2) Ventana | VG-1 | 1:200, 60 minutes |
AbCam | |||
VEGF-C
| ptLink (pH = 9) Dako | 18-2255 | 1:200, 60 minutes |
Invitrogen | |||
VEGF-D
| ptLink (pH = 9) Dako | ab63068 | 1:50, 60 minutes |
AbCam | |||
VEGFR-1
| ptLink (pH = 9) Dako | ab9540 | 1:300, 60 minutes |
AbCam | |||
VEGFR-2
| ptLink (pH = 9) Dako | ab2349 | 1:100, 60 minutes |
AbCam | |||
VEGFR-3
| ptLink (pH = 9) Dako | ab72240 | 1:50, 60 minutes |
AbCam |
Immunohistochemical evaluation
Statistical analysis
Results
Human samples
MCT1
|
MCT4
|
CD147
|
GLUT1
|
CAIX
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive (%) |
p
| n | Positive (%) |
P
| n | Positive (%) |
p
| n | Positive (%) |
p
| n | Positive (%) |
p
| |
0.252 |
0.005
| 0.071 |
0.025
|
0.004
| |||||||||||
Cervicitis
|
28
| 6 (21.4) |
27
| 6 (22.2) |
24
| 0 (0.0) |
24
| 12 (50.0) |
26
| 11 (42.3) | |||||
LSIL
|
33
| 9 (27.3) |
30
| 8 (26.7) |
34
| 2 (5.9) |
34
| 29 (85.3) |
34
| 4 (11.8) | |||||
HSIL
|
28
| 9 (32.1) |
28
| 6 (21.4) |
29
| 2 (6.9) |
29
| 19 (65.5) |
29
| 8 (27.6) | |||||
SCC
|
34
| 15 (44.1) |
33
| 19 (57.6) |
32
| 6 (18.8) |
37
| 28 (75.7) |
33
| 17 (51.5) |
VEGF-A
|
VEGF-C
|
VEGFR-1
|
VEGFR-2
|
VEGFR-3
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive (%) |
p
| n | Positive (%) |
p
| n | Positive (%) |
p
| n | Positive (%) |
p
| n | Positive (%) |
p
| |
MCT1
|
0.013
| 1.000 | 0.370 | 0.426 | 0.722 | ||||||||||
Negative |
17
| 16 (94.1) |
19
| 18 (94.7) |
19
| 2 (10.5) |
19
| 14 (73.7) |
18
| 6 (33.3) | |||||
Positive |
15
| 8 (53.3) |
15
| 14 (93.3) |
15
| 4 (26.7) |
15
| 13 (86.7) |
15
| 4 (26.7) | |||||
MCT4
| 0.108 | 0.172 | 0.209 | 0.670 | 1.000 | ||||||||||
Negative |
12
| 11 (91.7) |
14
| 12 (85.7) |
14
| 1 (7.1) |
14
| 12 (85.7) |
14
| 4 (28.6) | |||||
Positive |
19
| 12 (63.2) |
19
| 19 (100.0) |
19
| 5 (26.3) |
19
| 14 (73.7) |
19
| 6 (31.6) | |||||
CD147
| 0.645 | 1.000 | 1.000 | 1.000 | 0.314 | ||||||||||
Negative |
24
| 18 (75.0) |
26
| 25 (96.2) |
26
| 5 (19.2) |
26
| 20 (76.9) |
26
| 6 (23.1) | |||||
Positive |
6
| 4 (66.7) |
6
| 6 (100.0) |
6
| 1 (16.7) |
6
| 5 (83.3) |
6
| 3 (50.0) | |||||
GLUT1
| 0.390 | 0.553 | 0.340 | 1.000 | 0.205 | ||||||||||
Negative |
8
| 7 (87.5) |
9
| 9 (100.0) |
9
| 3 (33.3) |
9
| 7 (77.8) |
8
| 4 (50.0) | |||||
Positive |
27
| 18 (66.7) |
26
| 23 (88.5) |
26
| 4 (15.4) |
26
| 21 (80.8) |
25
| 6 (24.0) | |||||
CAIX
| 0.685 | 0.485 | 0.175 | 0.398 | 0.909 | ||||||||||
Negative |
15
| 12 (80.0) |
16
| 16 (100.0) |
16
| 1 (6.2) |
16
| 14 (87.5) |
16
| 5 (31.2) | |||||
Positive |
16
| 11 (68.8) |
17
| 15 (88.2) |
17
| 5 (29.4) |
17
| 12 (70.6) |
17
| 5 (29.4) |
MCT1
|
MCT4
|
CD147
|
GLUT1
|
CAIX
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive (%) |
p
| n | Positive (%) |
p
| n | Positive (%) |
p
| n | Positive (%) |
p
| n | Positive (%) |
p
| |
Age*
| 0.901 |
0.029
|
0.024
| 0.711 | 0.208 | ||||||||||
> 48 |
14
| 6 (42.9) |
14
| 5 (35.7) |
14
| 0 (0.0) |
15
| 12 (80.0) |
14
| 9 (64.3) | |||||
≤ 48 |
20
| 9 (45.0) |
19
| 14 (73.7) |
18
| 6 (33.3) |
22
| 16 (72.7) |
19
| 8 (42.1) | |||||
Tumour size*
| 0.644 | 0.600 | 1.000 | 0.624 | 1.000 | ||||||||||
≤ 2 cm |
11
| 4 (36.4) |
11
| 7 (63.6) |
11
| 2 (18.2) |
14
| 10 (71.4) |
11
| 4 (36.4) | |||||
> 2 cm |
6
| 3 (50.0) |
6
| 5 (83.3) |
6
| 1 (16.7) |
7
| 6 (85.7) |
6
| 2 (33.3) | |||||
Clinical stage
| 0.634 | 0.138 | 1.000 | 0.307 | 0.335 | ||||||||||
I |
29
| 12 (41.4) |
28
| 18 (64.3) |
27
| 5 (18.5) |
32
| 23 (71.9) |
28
| 13 (46.4) | |||||
II |
5
| 3 (60.0) |
5
| 1 (20.0) |
5
| 1 (20.0) |
5
| 5 (100.0) |
5
| 4 (80.0) | |||||
VEGF-A
|
VEGF-C
|
VEGFR-1
|
VEGFR-2
|
VEGFR-3
| |||||||||||
n
|
Positive (%)
|
p
|
n
|
Positive (%)
|
p
|
n
|
Positive (%)
|
p
|
n
|
Positive (%)
|
p
|
n
|
Positive (%)
|
p
| |
Age*
| 0.270 | 1.000 | 0.681 | 1.000 | 0.455 | ||||||||||
> 48 |
13
| 11 (84.6) |
14
| 13 (92.9) |
14
| 2 (14.3) |
14
| 11 (78.6) |
14
| 3 (21.4) | |||||
≤ 48 |
23
| 15 (64.2) |
22
| 20 (90.9) |
22
| 5 (22.7) |
22
| 18 (81.8) |
19
| 7 (36.8) | |||||
Tumour size*
| 0.624 | 1.000 | 0.517 | 0.557 | 0.600 | ||||||||||
≤ 2 cm |
14
| 10 (71.4) |
13
| 12 (92.3) |
13
| 3 (23.1) |
13
| 11 (84.6) |
11
| 4 (36.4) | |||||
> 2 cm |
7
| 6 (85.7) |
6
| 6 (100.0) |
6
| 0 (0.0) |
6
| 4 (66.7) |
6
| 1 (16.7) | |||||
Clinical stage
| 0.603 | 0.370 | 0.559 | 0.244 | 0.627 | ||||||||||
I |
31
| 23 (74.2) |
31
| 29 (93.5) |
31
| 7 (22.6) |
31
| 26 (83.9) |
28
| 8 (28.6) | |||||
II |
5
| 3 (60.0) |
5
| 4 (80.0) |
5
| 0 (0.0) |
5
| 3 (60.0) |
5
| 2 (40.0) |